Verified facts
Smith+Nephew reports quarterly revenue of $1.551bn, up 3.4% on both reported and underlying bases. It has reduced full-year underlying revenue-growth guidance to around 3%, from around 4%, reflecting its US hips and knees outlook and market conditions.
Trading profit is now expected to be about $1.25bn, previously about $1.3bn. These are forecasts, not reported annual earnings. The company also says earlier discussions with Johnson & Johnson about a possible combination have ended, while its review of options for Orthopaedics continues.
Apolifina analysis
The update shows why a growing quarter does not necessarily support an unchanged annual forecast. Investors should distinguish operating improvement from the expectations already built into the business plan.
The strategic review does not establish that a sale, merger or other transaction will take place. It should not be illustrated as a completed deal.
Uncertainty and risk
Demand, execution and strategic decisions remain uncertain. Trading profit is an adjusted measure, not statutory earnings. General information, not medical or investment advice.
Primary sources
Source released 4 November 2026. Published 17 November 2026.
Continue reading: GSK results · Ibstock outlook
